Mirta Díez
A5051957671- Heart Failure Treatment and Management
- Cardiovascular Function and Risk Factors
- Mechanical Circulatory Support Devices
- Diabetes Treatment and Management
- Cardiac Structural Anomalies and Repair
- Cardiomyopathy and Myosin Studies
- Viral Infections and Immunology Research
- Pulmonary Hypertension Research and Treatments
- Metabolism, Diabetes, and Cancer
- Transplantation: Methods and Outcomes
- Cardiac pacing and defibrillation studies
- Pancreatic function and diabetes
- Cardiovascular Issues in Pregnancy
- Acute Myocardial Infarction Research
- Trypanosoma species research and implications
- Atrial Fibrillation Management and Outcomes
- Cardiac Arrest and Resuscitation
- Cardiac Valve Diseases and Treatments
- Renal Transplantation Outcomes and Treatments
- Cardiovascular Effects of Exercise
- Cardiac Arrhythmias and Treatments
- Congenital Heart Disease Studies
- Ultrasound in Clinical Applications
- Vascular Anomalies and Treatments
- Cardiac Health and Mental Health
Instituto Cardiovascular de Buenos Aires
2015-2025
British Heart Foundation
2020
Spanish National Centre for Cardiovascular Research
2020
Favaloro Foundation
2004-2012
Fundacion Favaloro Hospital Universitario
2007-2012
Consejo Nacional de Investigaciones Científicas y Técnicas
2007-2012
Hospital Universitario Puerta del Mar
2010
Universidad de Granada
2008
In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter (SGLT2) reduce the risk a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding effects SGLT2 in established failure and reduced ejection fraction, regardless presence or absence diabetes.
Additional treatments are needed for heart failure with reduced ejection fraction (HFrEF). Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be an effective treatment patients HFrEF, even those without diabetes.To evaluate the effects of dapagliflozin in HFrEF and diabetes.Exploratory analysis a phase 3 randomized trial conducted at 410 sites 20 countries. Patients New York Heart Association classification II to IV less than or equal 40% elevated plasma N-terminal pro B-type natriuretic...
This report describes a real-time PCR (Q-PCR) strategy to quantify Trypanosoma cruzi (T. cruzi) DNA in peripheral blood samples from Chagas disease patients targeted conserved motifs within the repetitive satellite sequence.The Q-PCR has detection limit of 0.1 and 0.01 parasites/mL, with dynamic range 10(6) 10(7) for Silvio X10 cl1 I) Cl Brener stocks IIe), respectively, an efficiency 99%, coefficient determination (R(2)) 0.998. In order express accurately parasitic loads: (1) we adapted...
Goals of management in patients with heart failure and reduced ejection fraction include reducing death hospitalizations, improving health status (symptoms, physical function, quality life). In the DAPA-HF trial (Dapagliflozin Prevention Adverse-Outcomes Heart Failure), sodium-glucose cotransporter-2 inhibitor, dapagliflozin, improved symptoms fraction. this analysis, we examine effects dapagliflozin on a broad range outcomes, using Kansas City Cardiomyopathy Questionnaire (KCCQ).KCCQ was...
In the DAPA-HF trial, SGLT2 inhibitor dapagliflozin reduced risk of worsening heart failure (HF) and death in patients with HF ejection fraction. We examined whether this benefit was consistent relation to background therapy.
One hundred years after the discovery of Chagas disease, it remains a major neglected tropical disease. Chronic heart disease (cChHD) is most severe manifestation. Heart transplantation proper treatment for end-stage failure, although reactivation may result receipt immunosuppressive therapy. T. cruzi strains cluster into 6 discrete typing units (DTUs; I-VI) associated with different geographical distribution, transmission cycles and varying symptoms. In southern cone South America, II, V,...
Concern about hypotension often leads to withholding of beneficial therapy in patients with heart failure and reduced ejection fraction (HFrEF). We evaluated the efficacy safety dapagliflozin, which lowers systolic blood pressure (SBP),according baseline SBP Dapagliflozin Prevention Adverse Outcomes Heart Failure trial (DAPA-HF).
OBJECTIVE The sodium–glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of cardiovascular mortality and worsening heart failure in Dapagliflozin Prevention Adverse Outcomes Heart Failure (DAPA-HF) trial. This report explores effect on incident type diabetes (T2D) cohort without enrolled RESEARCH DESIGN AND METHODS subgroup 2,605 patients with ejection fraction (HFrEF), no prior history diabetes, an HbA1c <6.5% at baseline was randomized to 10 mg daily or placebo. In this...
This study sought to investigate the efficacy and safety of dapagliflozin in Black White patients with heart failure (HF) reduced ejection fraction (HFrEF) enrolled DAPA-HF (Study Evaluate Effect Dapagliflozin on Incidence Worsening Heart Failure or Cardiovascular Death Patients With Chronic Failure).Black may respond differently certain treatments for HFrEF than patients.Patients New York Association functional class II IV an ≤40% elevated N-terminal pro-B-type natriuretic peptide were...
SUMMARY Genetic diversity of Trypanosoma cruzi may play a role in pathogenesis Chagas disease forms. Natural populations are classified into 6 Discrete Typing Units (DTUs) Tc I-VI with taxonomical status. This study aimed to identify T. DTUs bloodstream and tissue samples Argentinean patients disease. PCR-based strategies allowed DTU identification 256 clinical from 239 patients. V prevailed blood both asymptomatic symptomatic cases I was more frequent bloodstream, cardiac tissues chagoma...
<h3>Importance</h3> Women may respond differently to certain treatments for heart failure (HF) with reduced ejection fraction (HFrEF) than men. <h3>Objective</h3> To investigate the efficacy and safety of dapagliflozin compared placebo in men women HFrEF enrolled Dapagliflozin Prevention Adverse Outcomes Heart Failure trial (DAPA-HF). <h3>Design, Setting, Participants</h3> Prespecified subgroup analysis a phase 3 randomized clinical conducted at 410 sites 20 countries. Patients New York...
OBJECTIVE To determine whether the benefits of dapagliflozin in patients with heart failure and reduced ejection fraction (HFrEF) type 2 diabetes Dapagliflozin And Prevention Adverse-Outcomes Heart Failure trial (DAPA-HF) varied by background glucose-lowering therapy (GLT). RESEARCH DESIGN AND METHODS We examined effect study treatment use or not GLT classes combinations. The primary outcome was a composite worsening (hospitalization urgent visit requiring intravenous therapy) cardiovascular...
Reflecting both increased venous pressure and reduced cardiac output, abnormal liver tests are common in patients with severe heart failure associated adverse clinical outcomes. We aimed to investigate the prognostic significance of ambulatory ejection fraction (HFrEF), explore any treatment interaction between bilirubin sodium-glucose cotransporter 2 (SGLT2) inhibitors examine change SGLT2 inhibitor treatment.We explored these objectives Dapagliflozin And Prevention Adverse outcomes Heart...
Introduction: Patients hospitalized for heart failure with preserved ejection fraction (HFpEF) have a higher prevalence of anemia than those reduced (HFpEF). However, it is unknown if this relationship maintained in patients chronic kidney disease, forming cardiorenal syndrome type IV. Methods: Cross-sectional, multicenter study disease failure. The primary outcome was the difference hemoglobin concentration. secondary anemia. Results: 229 were enrolled. Hemoglobin concentration lower HFpEF...
Introducción: La oxigenación por membrana extracorpórea venoarterial (ECMO VA) es una intervención de rescate en pacientes con shock cardiogénico (SC), y paro cardiorrespiratorio (PCR) refractarios a las terapias convencionales.Objetivo: Describir características, resumir nuestra experiencia inicial 7 años que requirieron ECMO VA SC o PCR.Material métodos: Se realizó un estudio cohorte unicéntrico. analizaron retrospectivamente los adultos consecutivos fueron asistidos PCR entre 2014 2020 el...
Objectives We aimed to assess safety and, secondarily, the efficacy of intramyocardial high‐dose plasmid‐vascular endothelial growth factor (VEGF) 165 (pVEGF165) gene transfer in no‐option patients with coronary artery disease (CAD). Background Controlled trials pVEGF165 CAD have shown little benefit. One possible reason is shortness dosage. large mammalian models chronic myocardial ischemia and acute infarction that at doses significantly higher than those used recent phase II safe...
ObjectiveThe soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic (CTEPH) following Phase 3 randomized trials. The EXPosurE Registry RiociguaT in (EXPERT) study was designed to monitor long-term safety clinical practice.MethodsEXPERT an international, multicenter, prospective, uncontrolled, non-interventional cohort treated riociguat. Patients...